NHS England has today published a draft commercial framework, setting out more operational detail on commercial arrangements with industry. There will now be an engagement process to make sure that the final framework is informed by a broad range of views.
In response to the publication, Paul Catchpole, Director, Value and Access Policy at the ABPI said:
"We welcome today’s publication of the draft NHSE commercial framework, which was a key commitment set out in the Voluntary Scheme. The framework sets out how companies can work with NHSE to ensure that patients can get early access to new innovative medicines.
"We look forward to taking part in the engagement process to ensure that the framework meets the needs of all stakeholders including patients, NHSE, NICE and industry."
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
To read more Press Release articles, click here.